Urinary tract infection in the users of depot-medroxyprogesterone acetate

被引:5
|
作者
Ziaei, S [1 ]
Ninavaei, M [1 ]
Faghihzadeh, S [1 ]
机构
[1] Tarbiat Modarres Univ, Dept Obstet & Gynecol, Fac Med Sci, Tehran, Iran
关键词
depot-medroxyprogesterone acetate; urinary tract infection; urological symptoms;
D O I
10.1111/j.0001-6349.2004.00296.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background. The effects of progesterone on muscle tone, peristalsis of the ureter and also urinary vasculature may cause urinary tract infection (UTI) in women who use depot-medroxyprogesterone acetate (DMPA) for contraception. Methods. In a cohort study, 200 women who chose DMPA for contraception were compared with 200 women who used the withdrawal method for urinary infection and urological symptoms after 3 months of consumption. Results. The rate of urinary infection and urological symptoms in the study group were higher than in the control group (p = 0.018, p < 0.0001, respectively). The most common microorganism that caused urinary infection was Escherichia coli. Among the 10 cases who suffered UTI in the case group, there were six women who had UTI in the previous pregnancy as well. Conclusion. We do not recommended administering depot-medroxyprogesterone acetate for contraception in women with a history of urinary tract infection in a previous pregnancy.
引用
收藏
页码:909 / 911
页数:3
相关论文
共 50 条
  • [1] Depot-medroxyprogesterone acetate: an update
    Bakry, Sayed
    Merhi, Zaher O.
    Scalise, Trudy J.
    Mahmoud, Mohamad S.
    Fadiel, Ahmed
    Naftolin, Frederick
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2008, 278 (01) : 1 - 12
  • [2] Depot-medroxyprogesterone acetate: an update
    Sayed Bakry
    Zaher O. Merhi
    Trudy J. Scalise
    Mohamad S. Mahmoud
    Ahmed Fadiel
    Frederick Naftolin
    [J]. Archives of Gynecology and Obstetrics, 2008, 278 : 1 - 12
  • [3] Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive
    Pantoja, Marcia
    Medeiros, Tatiane
    Baccarin, Maria Carolina
    Morais, Sirlei Siani
    Bahamondes, Luis
    dos Santos Fernandes, Arlete Maria
    [J]. CONTRACEPTION, 2010, 81 (02) : 107 - 111
  • [4] Weight and body fat changes in postpartum depot-medroxyprogesterone acetate users
    Nyirati, Christina M.
    Habash, Diane L.
    Shaffer, Lynn E. T.
    [J]. CONTRACEPTION, 2013, 88 (01) : 169 - 176
  • [5] Effect of the injectable contraceptive depot-medroxyprogesterone acetate on coagulation parameters in new users
    Melhado-Kimura, Vaneska
    Annichino Bizzacchi, Joyce Maria
    Picoli Quaino, Susan Kelly
    Montalvao, Silmara
    Bahamondes, Luis
    Fernandes, Arlete
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2017, 43 (06) : 1054 - 1060
  • [6] Risk of HIV Infection in Depot-Medroxyprogesterone Acetate (DMPA) Users: A Systematic Review and Meta-Analysis
    Brind, Joel
    Condly, Steven J.
    Mosher, Steven W.
    Morse, Anne R.
    Kimball, Jennifer
    [J]. ISSUES IN LAW & MEDICINE, 2015, 30 (02) : 129 - 139
  • [8] Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi
    Zia, Yasaman
    Tang, Jennifer H.
    Chinula, Lameck
    Tegha, Gerald
    Stanczyk, Frank Z.
    Kourtis, Athena P.
    [J]. CONTRACEPTION, 2019, 100 (05) : 402 - 405
  • [9] DEPOT-MEDROXYPROGESTERONE ACETATE (DMPA) AND CANCER OF THE ENDOMETRIUM AND OVARY
    LUMBIGANON, P
    [J]. CONTRACEPTION, 1994, 49 (03) : 203 - 209
  • [10] BREAST-CANCER AND DEPOT-MEDROXYPROGESTERONE ACETATE - A REVIEW
    CHILVERS, C
    [J]. CONTRACEPTION, 1994, 49 (03) : 211 - 222